EN | UA
EN | UA

Help Support

Back

Personalized therapy reduces pelvic pain and improves quality of life

Personalized therapy reduces pelvic pain and improves quality of life Personalized therapy reduces pelvic pain and improves quality of life
Personalized therapy reduces pelvic pain and improves quality of life Personalized therapy reduces pelvic pain and improves quality of life

What's new?

In patients with pelvic pain, personalized therapy can alleviate pain and also enhance the patient's quality of life.

Using personalized therapy (administration of celecoxib to 70 carriers of the CYP2C9 NM genotype at an average dose of 200 mg /day once, to 32 carriers of the aceclofenac PM genotype 200 mg /day in two doses) aids to attain a better result like decrease in pain intensity, an improvement in the major indicators of quality of life, while ensuring safety and minimizing CPD, by reducing the gastrointestinal tract and cardiovascular system complications.

This study aimed to investigate the quality of life of people having chronic pelvic pain syndrome (CPPS) before and after prescription of non-steroidal anti-inflammatory drugs (NSAIDs), depending on the severity of the pain syndrome, the presence of comorbid pathology, the CYP2C9 genotype that assesses the rate of the metabolic reactions and risk of side effects.

In CPPS people, the carriage of variants of CYP2C9 gene mutations was explored (mean age 49.7 ± 13.43 years, men - 71, women – 81). Considering the presence of comorbid pathology and the outcomes of pharmacogenetic testing, personalized therapy with NSAIDs was chosen. The intensity of pain syndrome (visual analogue scale [VAS]), the quality of life (World Health Organization  Brief Questionnaire [WHOQOL BREF]), and the concentration of pro-inflammatory cytokines (interleukin-1β, interleukin-6) was estimated prior to initiation of treatment and on the 7th day of NSAID treatment.

With personalized treatment, a considerable decline in pain intensity and level of pro-inflammatory cytokines in the blood, and a rise in the quality of life of participants was noted in all the observation groups. In addition, in individuals receiving personalized therapy with NSAIDs, minimum development of undesirable adverse reactions was noted.

Source:

Russian Journal of Pain

Article:

The impact of personalized therapy on the quality of life of patients with chronic pelvic pain syndrome

Authors:

Mamina R.M et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: